iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio

Achievement strengthens iBio’s partnered cardiometabolic and obesity program while showcasing its proprietary AI-driven drug and target discovery platform potentialSAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the development of an antibody that inhibits the function of Activin E, a promising therapeutic target for cardiometabolic disorders and obesity using iBio’s pat ...